Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).
Andrew Eugene Hendifar
No relevant relationships to disclose
Sant P. Chawla
No relevant relationships to disclose
Michael Gordon Leahy
No relevant relationships to disclose
Antoine Italiano
No relevant relationships to disclose
Shreyaskumar Patel
Research Funding - Astex Therapeutics; Eisai; Infinity; Johnson & Johnson; PharmaMar
Armando Santoro
No relevant relationships to disclose
Arthur P. Staddon
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Sophie Piperno-Neumann
No relevant relationships to disclose
George D. Demetri
No relevant relationships to disclose
Larry Hayward
No relevant relationships to disclose
Jeff White
No relevant relationships to disclose
Launce G. Gouw
No relevant relationships to disclose
Bernardo De Miguel
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Pilar Lardelli
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Arturo Soto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Antonio Nieto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - MSD (U)